Is It Worth Correcting Hyperparathyroidism if Hyperphosphatemia and Hypocalcemia Worsen? A Cinacalcet Story

American Journal of Kidney Diseases

Volumn 53, Issue 2, 2009, Pages 183-188

  Kalantar Zadeh, Kamyar ^a   Kovesdy, Csaba P ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CALCIUM SENSING RECEPTOR; CINACALCET; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO; VITAMIN D;

ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DISEASE; CALCITONIN BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DRUG ACTIVITY; EDITORIAL; HUMAN; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY GRAFT; PARATHYROID HORMONE RELEASE; PHOSPHATE BLOOD LEVEL;

CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE, CHRONIC; NAPHTHALENES; PHOSPHORUS;

EID: 58349104392     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.12.002     Document Type: Editorial

References (51)

1. Moe S.M., Drueke T., Lameire N., and Eknoyan G. Chronic kidney disease-mineral-bone disorder: A new paradigm. Adv Chronic Kidney Dis 14 (2007) 3-12
2. Kovesdy C.P., and Kalantar-Zadeh K. Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol 40 (2008) 427-440
3. Chonchol M., Locatelli F., Abboud H.E., et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis 53 (2009) 197-207
4. Cinacalcet: AMG 073, Calcimimetics-Amgen/NPS Pharmaceuticals, KRN 1493, NPS 1493. Drugs R D 4 (2003) 349-351
5. Valle C., Rodriguez M., Santamaria R., et al. Cinacalcet reduces the set point of the PTH-calcium curve. J Am Soc Nephrol 19 (2008) 2430-2436
6. Narayan R., Perkins R.M., Berbano E.P., et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: A cost utility analysis. Am J Kidney Dis 49 (2007) 801-813
7. Wang H.Y., Yu C.C., and Huang C.C. Successful treatment of severe calciphylaxis in a hemodialysis patient using low-calcium dialysate and medical parathyroidectomy: Case report and literature review. Ren Fail 26 (2004) 77-82
8. Lazar E.S., and Stankus N. Cinacalcet-induced hungry bone syndrome. Semin Dial 20 (2007) 83-85
9. Fukagawa M., Yumita S., Akizawa T., et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 23 (2008) 328-335
10. Descombes E., Vogel G., Rosman J., and Wauters J.P. High frequency of marked hyperphosphatemia during intravenous calcitriol therapy in hemodialysis patients with refractory hyperparathyroidism. Blood Purif 14 (1996) 234-241
11. Coyne D., Acharya M., Qiu P., et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47 (2006) 263-276
12. Serra A.L., Wuhrmann C., and Wuthrich R.P. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis 53 (2008) 1151-1157
13. Repo J.M., Rantala I.S., Honkanen T.T., et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 72 (2007) 977-984
14. Belozeroff V., Goodman W.G., Ren L., and Kalantar-Zadeh K. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2009) (in press)
15. Esposito L., Rostaing L., Gennero I., Mehrenberger M., Durand D., and Kamar N. Hypercalciuria induced by a high dose of cinacalcet in a renal-transplant recipient. Clin Nephrol 68 (2007) 245-248
16. Borchhardt K.A., Heinzl H., Mayerwoger E., Horl W.H., Haas M., and Sunder-Plassmann G. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 86 (2008) 919-924
17. Coyne D.W., Grieff M., Ahya S.N., Giles K., Norwood K., and Slatopolsky E. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 40 (2002) 1283-1288
18. Charytan C., Coburn J.W., Chonchol M., et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 46 (2005) 58-67
19. United States Food and Drug Administration (USFDA). USFDA Sensipar (Cinacalcet HCI) Tablets Approval Application No. 021688. http://www.fda.gov/cder/foi/nda/2004/21-688_Sensipar.htm Accessed July 5, 2004
20. Coyne D.W. Cinacalcet should not be used to treat secondary hyperparathyroidism in stage 3-4 chronic kidney disease. Nat Clin Pract Nephrol 4 (2008) 364-365
21. Serra A.L., Braun S.C., Starke A., et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant 8 (2008) 803-810
22. Gutierrez O., Isakova T., Rhee E., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16 (2005) 2205-2215
23. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008) 584-592
24. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., and Kalantar-Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 73 (2008) 1296-1302
25. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (2006) 771-780
26. Shinaberger C.S., Kopple J.D., Kovesdy C.P., et al. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1769-1776
27. Kalantar-Zadeh K., Duong U., Miller J.E., Dezfuli A., and Kovesdy C.P. Kidney bone disease and mortality in CKD: the role of vitamin D, alkaline phosphatase and minerals. Kidney Int Suppl (2009) (in press)
28. Kovesdy C.P., and Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 73 (2008) 1355-1363
29. Cunningham J., Danese M., Olson K., Klassen P., and Chertow G.M. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68 (2005) 1793-1800
30. Messa P., Macario F., Yaqoob M., et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3 (2008) 36-45
31. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70 (2006) 351-357
32. Spodick D.H. Hypocalcemia, hyperkalemia, and junctional or sinoventricular rhythm. Am J Geriatr Cardiol 14 (2005) 273
33. Spodick D.H. Classic chronic renal failure: hyperkalemia and hypocalcemia. Am J Geriatr Cardiol 14 (2005) 336-337
34. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 suppl 3 (2003) S1-S202
35. O'Neill W.C. The fallacy of the calcium-phosphorus product. Kidney Int 72 (2007) 792-796
36. Goodman W.G., Goldin J., Kuizon B.D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342 (2000) 1478-1483
37. Braun J., Oldendorf M., Moshage W., Heidler R., Zeitler E., and Luft F.C. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27 (1996) 394-401
38. Moe S.M. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 36 suppl 2 (2006) 51-62
39. Kestenbaum B., Sampson J.N., Rudser K.D., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16 (2005) 520-528
40. Slatopolsky E., Brown A., and Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73 (1999) S14-S19
41. Ba J., and Friedman P.A. Calcium-sensing receptor regulation of renal mineral ion transport. Cell Calcium 35 (2004) 229-237
42. Malluche H.H., Monier-Faugere M.C., Wang G., et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69 (2008) 269-278
43. Regidor D.L., Kovesdy C.P., Mehrotra R., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 19 (2008) 2193-2203
44. Lindberg J.S., Culleton B., Wong G., et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16 (2005) 800-807
45. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350 (2004) 1516-1525
46. Moe S.M., Chertow G.M., Coburn J.W., et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67 (2005) 760-771
47. Schaefer R.M., Bover J., Dellanna F., et al. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clin Nephrol 70 (2008) 126-134
48. Sterrett J.R., Strom J., Stummvoll H.K., et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 68 (2007) 10-17
49. Kooh S.W., Fraser D., DeLuca H.F., et al. Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: Evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D. N Engl J Med 293 (1975) 840-844
50. Bergua C., Torregrosa J.V., Fuster D., Gutierrez-Dalmau A., Oppenheimer F., and Campistol J.M. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 86 (2008) 413-417
51. Kovesdy C.P., Mehrotra R., and Kalantar-Zadeh K. Battleground: Chronic kidney disorders mineral and bone disease-calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol 3 (2008) 168-173